Literature DB >> 7655784

Day-to-day titration of transdermal fentanyl is unwise.

D Brooks.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7655784     DOI： 10.1007/bf00368895

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  7 in total

1.  Transdermal fentanyl: pharmacokinetics and preliminary clinical evaluation.

Authors:  P M Plezia; T H Kramer; J Linford; S R Hameroff
Journal:  Pharmacotherapy       Date:  1989       Impact factor: 4.705

2.  Narcotic use in the hospital: reasonably safe?

Authors:  J K Whipple; R K Ausman; E J Quebbeman
Journal:  Ann Pharmacother       Date:  1992 Jul-Aug       Impact factor: 3.154

3.  Absorption characteristics of transdermally administered fentanyl.

Authors:  J R Varvel; S L Shafer; S S Hwang; P A Coen; D R Stanski
Journal:  Anesthesiology       Date:  1989-06       Impact factor: 7.892

4.  Transdermal fentanyl in uncontrolled cancer pain: titration on a day-to-day basis as a procedure for safe and effective dose finding--a pilot study in 20 patients.

Authors:  W Korte; R Morant
Journal:  Support Care Cancer       Date:  1994-03       Impact factor: 3.603

5.  Transdermal fentanyl and initial dose-finding with patient-controlled analgesia in cancer pain. A pilot study with 20 terminally ill cancer patients.

Authors:  Detlev F J Zech; Stefan U A Grond; John Lynch; Hans G Dauer; Bernd Stollenwerk; Klaus A Lehmann
Journal:  Pain       Date:  1992-09       Impact factor: 6.961

6.  Transdermal fentanyl for chronic cancer pain: detailed case reports and the influence of confounding factors.

Authors:  R B Patt; L A Hogan
Journal:  J Pain Symptom Manage       Date:  1992-04       Impact factor: 3.612

7.  Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics.

Authors:  R K Portenoy; M A Southam; S K Gupta; J Lapin; M Layman; C E Inturrisi; K M Foley
Journal:  Anesthesiology       Date:  1993-01       Impact factor: 7.892
  7 in total
  2 in total

Review 1.  Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl.

Authors:  S Grond; L Radbruch; K A Lehmann
Journal:  Clin Pharmacokinet       Date:  2000-01       Impact factor: 6.447

Review 2.  Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain.

Authors:  Craig A Kornick; Juan Santiago-Palma; Natalia Moryl; Richard Payne; Eugenie A M T Obbens
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.